Prevalence and treatment outcome in anxious versus nonanxious depression: Results from the German algorithm project

Journal of Clinical Psychiatry

Volumn 71, Issue 8, 2010, Pages 1047-1054

  Wiethoff, Katja ^a   Bauer, Michael ^d   Baghai, Thomas C ^e   Möller, Hans Jürgen ^e   Fisher, Robert ⁱ   Hollinde, Dorothea ^a   Kiermeir, Julia ^a   Hauth, Iris ^b   Laux, Gerd ^f   Cordes, Joachim ^g   Brieger, Peter ^f   Kronmüller, Klaus Thomas ^h   Zeiler, Joachim ^c   Adli, Mazda ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ST JOSEPH KRANKENHAUS   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Bezirksklinikum Gabersee ^*  (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ALGORITHM; ANXIETY DISORDER; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 77956001512     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05650blu     Document Type: Article

References (39)

1. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15(4):357-376.
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627.
3. Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365-374.
4. Melartin TK, Rytsälä HJ, Leskelä US, et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry. 2002;63(2):126-134.
5. Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Supp. 1998;34:24-28.
6. Sanderson WC, Beck AT, Beck J. Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships. Am J Psychiatry. 1990;147(8):1025-1028.
7. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry. 2002;63(3):187-193.
8. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299-1308.
9. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51(13):823-835.
10. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150(8):1257-1258.
11. Van Valkenburg C, Akiskal HS, Puzantian V, et al. Anxious depressions: clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord. 1984;6(1):67-82.
12. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148(11):1512-1517.
13. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351.
14. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55(2):50-59.
15. Flint AJ, Rifat SL. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107-115.
16. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16(1):4-13.
17. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13(1):18-27.
18. Papakostas GI, McGrath P, Stewart J, et al. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008;161(1):116-120.
19. Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002;63(9):782-790.
20. Bauer M, Pfennig A, Linden M, et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol. 2009;29(4):327-333.
21. Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? a systematic review. Biol Psychiatry. 2006;59(11):1029-1038.
22. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
24. Wittchen HU, Wunderlich U, Gruschwitz MS, et al. SKID-I, Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe; 1997a.
25. Wittchen HU, Zaudig M, Fydrich T. SKID: Strukturiertes Klinisches Interview für DSM-IV, Achse II. Göttingen: Hogrefe; 1997b.
26. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
27. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A New Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand suppl. 1987;76(s334):1-100.
28. Cording C, Gaebel W, Spengler A. Die neue psychiatrische basisdokumentation. Eine empfehlung der DGPPN zur qualitätssicherung im (teil-)stationären bereich (The new psychiatric basic documentation. A recommendation by the DGPPN for quality assurance in inpatient treatment). Spektrum Psychiatrie Nervenheilkunde; 1995;24:3-41.
29. Cleary P, Guy W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res. 1977;1:115-120.
30. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97-102.
31. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161(12):2222-2229.
32. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry. 2008;10(3):222-228.
33. Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev. 2002;1(1):CD001026.
34. Silverstone PH, von Studnitz E. Defining anxious depression: going beyond comorbidity. Can J Psychiatry. 2003;48(10):675-680.
35. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287-1292.
36. Bandelow B, Zohar J, Hollander E, et al; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008;9(4):248-312.
37. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126(7):983-987.
38. Kendler KS. The nosologic validity of paranoia (simple delusional disorder): a review. Arch Gen Psychiatry. 1980;37(6):699-706.
39. Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol. 2010;20(5):301-309.